ClinicalTrials.gg
RecruitingNCT07827625Updated Sep 18, 2026

Mulligan Mobilization With Movement Versus Conventional Physiotherapy on Ankle Range of Motion, Mobility, Pain, and Quality of Life in Patients With Type 2 Diabetes Mellitus

An interventional study of Experimental and Control in Type 2 Diabetes Mellitus (DM), sponsored by Ibadat International University, Islamabad. Recruiting at 1 site in Pakistan. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Ibadat International University, Islamabad · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Mar 2026, registered Sep 2026).
  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 98 studies in Diabetes Mellitus, Type 2 with a site in Pakistan — 28 open to participants now, 35 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Pakistan.

Planned enrollment
63rd of 89
56 · median 99
Started
2026
with 15 others
No phase
59 of 98
19 open now
Primary completion
2026-09
later than 19 of 34 live
Registered
94th of 98
by date

Among the 98 studies in Diabetes Mellitus, Type 2 with a site in Pakistan, this one is the 63rd largest by planned enrollment of the 89 interventional ones that give a count, is one of 16 that started in 2026, is one of 59 with no phase, reaches primary completion later than 19 of the 34 other live ones, and was the 94th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

28 of the 98 studies in Diabetes Mellitus, Type 2 with a site in Pakistan are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 50 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Diabetes Mellitus, Type 2 with a site in Pakistan, or all of them as a file.
02

Study summary

Type 2 Diabetes Mellitus (T2DM) is a major global health concern associated with chronic hyperglycemia, oxidative stress, and accumulation of advanced glycation end-products, which impair connective tissue function and commonly restrict ankle (tibiotalar) mobility. Reduced ankle range of motion, neuropathic pain, and gait instability significantly impair daily activities and quality of life in this population, and reduced ankle mobility is further associated with increased risk of diabetic foot ulceration. Conventional physiotherapy is widely used to address these impairments through exercise, stretching, and strengthening, but may not fully resolve mechanical joint restrictions. Mulligan's Mobilization with Movement (MWM) is a manual therapy technique in which a sustained glide is applied to the ankle during active weight-bearing movement, correcting positional faults and improving dorsiflexion range of motion. While MWM has shown benefit in non-diabetic ankle conditions, its effectiveness relative to conventional physiotherapy in patients with T2DM remains unclear.

This study is a randomized controlled trial comparing the effects of Mulligan Mobilization with Movement (Group A) versus conventional physiotherapy (Group B) on pain intensity, ankle range of motion, functional mobility, and quality of life in adults aged 50-70 years with Type 2 Diabetes Mellitus of more than 5 years' duration. A total of 56 participants will be recruited using non-probability purposive sampling and randomly allocated by coin-toss method into two equal groups of 28. Both groups will receive baseline treatment (hot pack application and gentle active ankle movement) followed by their assigned protocol - Group A receiving MWM (sustained anteroposterior/posteroanterior glide to the distal tibia or fibula during active dorsiflexion or plantarflexion, 3 sets of 10 repetitions) and Group B receiving conventional physiotherapy (active/passive range-of-motion exercises, calf raises, and calf/Achilles stretching) - three sessions per week for six weeks.

Outcomes will be assessed at baseline and following the six-week intervention period. Primary outcome measures include pain intensity (Numeric Pain Rating Scale), ankle range of motion (goniometer), functional mobility (Timed Up and Go test), and quality of life (SF-12 Health Survey). Data will be analyzed using IBM SPSS Statistics version 27, with normality assessed via the Shapiro-Wilk test and within- and between-group comparisons made using parametric or non-parametric tests as appropriate.

This trial is expected to generate direct comparative evidence on whether Mulligan Mobilization with Movement offers superior outcomes to conventional physiotherapy for ankle-related impairments in patients with T2DM, helping physiotherapists select more targeted, evidence-based rehabilitation protocols for this population.

Read the detailed description

Type 2 Diabetes Mellitus is characterized by impaired insulin secretion and reduced insulin sensitivity resulting in chronic hyperglycemia. Pakistan ranks among the top ten countries globally for diabetes prevalence, with an estimated 7.5 million affected adults and no national diabetes management strategy. Chronic hyperglycemia drives collagen glycation and accumulation of advanced glycation end-products, causing tendon and joint-capsule stiffness, structural changes in the Achilles tendon and plantar fascia, and loss of ankle dorsiflexion; peripheral neuropathy further impairs proprioception and reinforces ankle hypomobility. Physiotherapy management, by improving available range of motion and normalizing foot and ankle biomechanics during gait, is a proposed conservative approach to these impairments. Mulligan's Mobilization with Movement (MWM) is an interactive manual therapy technique in which a sustained posterior talar glide is applied during active weight-bearing dorsiflexion, correcting talar positional faults and improving dorsiflexion range of motion. Rao and colleagues found that individuals with diabetes mellitus show markedly reduced ankle dorsiflexion compared with non-diabetic controls (peak dorsiflexion of 5.1° versus 11.5°, a roughly 41% reduction, p\<0.001) along with greater passive ankle stiffness, supporting the use of a dorsiflexion cutoff to identify patients most likely to benefit from targeted intervention.

Existing literature supports MWM's benefit in non-diabetic ankle conditions (e.g., acute/subacute lateral ankle sprain, chronic stroke) and supports multi-component foot/ankle exercise programs in diabetic populations, but no identified trial has directly compared MWM to conventional physiotherapy specifically in patients with T2DM-related ankle impairment, leaving a clear evidence gap that this trial addresses.

Problem Statement Patients with Type 2 Diabetes Mellitus commonly present with reduced ankle mobility, impaired balance, pain, and decreased quality of life due to diabetes-related musculoskeletal changes. Although conventional physiotherapy is routinely used, there is limited evidence comparing its effectiveness with Mulligan Mobilization with Movement in this population, and MWM's effectiveness in individuals with T2DM remains unclear.

Study Design and Methods This is a randomized controlled trial. Eligible participants are adults aged 50-70 years with Type 2 Diabetes Mellitus of more than 5 years' duration, both male and female, willing to provide informed consent, with pain rated 3-7 on the Numeric Pain Rating Scale and ankle dorsiflexion range of motion ≤10° on goniometric assessment. Individuals with recent lower-limb surgery, fracture or dislocation (\<6 months), active diabetic foot ulcer or Charcot foot, inflammatory joint disease, congenital foot deformity, or diagnosed diabetic peripheral neuropathy are excluded. A total of 56 participants, calculated using the OpenEpi Sample Size Calculator based on ankle dorsiflexion range of motion as the primary outcome, will be recruited via non-probability purposive sampling and randomized by coin-toss method into two groups of 28.

Both groups receive baseline treatment (hot pack to the ankle for 10-15 minutes and gentle active ankle movement within pain-free range). Group A then receives MWM: a sustained anteroposterior or posteroanterior glide to the distal tibia/fibula during active dorsiflexion or plantarflexion, 3 sets of 10 repetitions, each repetition held 3-5 seconds, with 30-60 seconds rest between sets, 30-40 minutes per session. Group B receives conventional physiotherapy: active and passive ankle range-of-motion exercises (dorsiflexion, plantarflexion, inversion, eversion), calf raises (10 reps × 3 sets), and calf/Achilles tendon stretching, 30-40 minutes per session, 10-15 repetitions × 2-3 sets. Both groups attend 3 sessions per week for 6 weeks.

Outcome Measures Four outcome domains are assessed at baseline and post-intervention (6 weeks): pain intensity via the Numeric Pain Rating Scale (NPRS, 0-10); ankle range of motion (dorsiflexion, plantarflexion) via goniometer; functional mobility via the Timed Up and Go (TUG) test; and quality of life via the SF-12 Health Survey.

Data Analysis and Ethics Statistical analysis will be carried out using IBM SPSS Statistics version 27. The Shapiro-Wilk test will assess normality. Within-group comparisons will use the paired-samples t-test (normal data) or Wilcoxon signed-rank test (non-normal data); between-group comparisons will use the independent-samples t-test (normal data) or Mann-Whitney U test (non-normal data). A p-value \< 0.05 will be considered statistically significant. The trial will be conducted under Research Ethics Review Committee approval, with written informed consent obtained from all participants, voluntary participation, and the right to withdraw at any time without affecting care or academic standing.

03

Conditions studied

  • Type 2 Diabetes Mellitus (DM)

Keywords

  • Mulligan Mobilization with Movement
  • ankle range of motion
  • quality of life
  • pain
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 50-70 years
  • Both male and female
  • Diabetes Mellitus > 5 years' duration
  • Willing to participate and provide
  • Pain rated between 3-7 on the Numeric Pain Rating Scale (NPRS)
  • Ankle dorsiflexion range of motion ≤10° on goniometric assessment

Exclusion criteria

Exclusion Criteria:

  • History of recent lower-limb surgery, fracture, or dislocation (\<6 months)
  • Active diabetic foot ulcer or Charcot foot
  • Any inflammatory joint disease (e.g., rheumatoid arthritis)
  • Congenital foot deformity
  • Diagnosed diabetic peripheral neuropathy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Group A

    Baseline: hot pack 10-15 min + gentle active ankle movement. Followed by Mulligan Mobilization with Movement: sustained AP/PA glide to distal tibia/fibula during active dorsiflexion/plantarflexion, 3 sets × 10 reps, each rep held 3-5s, 30-60s rest between sets. 30-40 min/session. 3 sessions/week for 6 weeks.

    Other: Experimental

  • Active comparator
    Group B

    Same baseline treatment as Group A. Followed by Conventional Physiotherapy: active/passive ankle ROM exercises (dorsiflexion, plantarflexion, inversion, eversion), calf raises 10×3 sets, calf/Achilles stretching. 30-40 min/session, 10-15 reps × 2-3 sets. 3 sessions/week for 6 weeks.

    Other: Control

Interventions

  • OtherExperimental

    Baseline: hot pack 10-15 min + gentle active ankle movement. Followed by Mulligan Mobilization with Movement: sustained AP/PA glide to distal tibia/fibula during active dorsiflexion/plantarflexion, 3 sets × 10 reps, each rep held 3-5s, 30-60s rest between sets. 30-40 min/session. 3 sessions/week for 6 weeks.

  • OtherControl

    Same baseline treatment as Group A. Followed by Conventional Physiotherapy: active/passive ankle ROM exercises (dorsiflexion, plantarflexion, inversion, eversion), calf raises 10×3 sets, calf/Achilles stretching. 30-40 min/session, 10-15 reps × 2-3 sets. 3 sessions/week for 6 weeks.

06

What researchers measure

Primary outcomes

  1. Numeric Pain Rating Scale (NPRS)

    0-10 self-reported pain intensity scale

    Time frame: assessed at baseline and post-intervention (6 weeks).

  2. Goniometer Measurement

    Dorsiflexion and plantarflexion measured in degrees using a goniometer;

    Time frame: assessed at baseline and post-intervention (6 weeks).

  3. Timed Up and Go (TUG) Test

    Time in seconds to rise from a chair, walk 3 meters, turn, and return

    Time frame: assessed at baseline and post-intervention (6 weeks).

  4. Quality of Life - SF-12

    12-item self-reported questionnaire assessing physical and mental health-related quality of life

    Time frame: assessed at baseline and post-intervention (6 weeks).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Sep 2026, 6 months after the start.

Of 2,072 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 6 months is below that.

Counting every sponsor, half of 2,249 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Sep 18, 2026
StartActual
Mar 2, 2026
Primary completionEst.
Sep 30, 2026
CompletionEst.
Oct 5, 2026
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07827625
Lead sponsor
Ibadat International University, Islamabad
Responsible party
Hafsah Arshad (Assistant professor, Ibadat International University, Islamabad) — Principal investigator
First posted
Sep 18, 2026
Start date
Mar 2, 2026
Primary completion
Sep 30, 2026 (estimated)
Completion
Oct 5, 2026 (estimated)
Last update
Sep 18, 2026

Study contacts

Nazish Jahangir, Master in MSK
Contact
Nazishjehanger@gmail.com
03125319484
Hafsah Arshad, PhD
principal investigator · Ibadat International University, Islamabad

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion